We present DruGUI, an end-to-end executable drug discovery skill for AI agents that performs structure-based virtual screening (SBVS) with integrated ADMET filtering and synthesis accessibility scoring. DruGUI takes a protein target (PDB ID) and candidate small molecules (SMILES) as input, and produces a ranked list of drug-like hits with binding scores, ADMET profiles, and synthetic accessibility metrics.
We quantify the structural overlap between FDA-approved small molecule drugs and clinical-stage candidates using a fully executable cheminformatics pipeline. Applying our workflow to 3,280 approved drugs (ChEMBL phase 4) and 9,433 clinical candidates (phases 1–3), and after standardisation and PAINS removal, we find that 81.
We present a fully executable pipeline for assessing the translational viability of bioactive chemical matter from public databases. Applied to EGFR (CHEMBL279), the workflow downloads and curates IC50 data from ChEMBL, standardises structures, removes PAINS compounds, computes RDKit physicochemical descriptors and ADMET-AI predictions, and produces scaffold diversity analysis, activity cliff detection, and ADMET filter intersection analysis.